RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…
RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…
RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…
RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…
RT @ScienceCrisp: [REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bha…
[REVIEW] #CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Ghosh D, Venkataramani P, Nandi S, Bhattacharjee S. Cancer Cell Int. 2019-01-08. https://t.co/nw1leodu2g https://t.co/y5sGDxwr0t